Navigation Links
China Non-Small Cell Lung Cancer Analysis & 2022 Forecasts in New Research Report at RnRMarketResearch.com
Date:9/21/2013

Dallas, TX (PRWEB) September 22, 2013

Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered on chemotherapy. However, the launch of targeted therapies for patients with specific biomarkers has begun to fragment the NSCLC treatment landscape into smaller niche patient populations. Over the forecast period, this trend will continue with the launch of multiple new drugs in several new drug classes to address the high unmet need among NSCLC patients, and provide new treatment options for previously underserved populations. Launch of premium-priced drug candidates combined with increasing incident cases of the disease will be major drivers of growth in the major markets.

Complete report is available at http://www.rnrmarketresearch.com/pharmapoint-non-small-cell-lung-cancer-china-drug-forecast-and-market-analysis-to-2022-market-report.html.

This report estimates that branded NSCLC market in China will grow in the forecast period. This increase will be due largely to an increasing aging population; increased use of EGFR and ALK targeted therapies and increased numbers of people covered by private health insurance.

Scope
Overview of NSCLC including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for the top drugs in China from 2012-2022.
Analysis of the impact of key events as well the drivers and restraints affecting China NSCLC market.

Reasons to Buy

  • Understand and Capitalize by Identifying Products That Are Most Likely to Ensure a Robust Return
  • Stay ahead of the competition by understanding the changing competitive landscape for NSCLC
  • Effectively Plan Your M&A and Partnership Strategies by Identifying Drugs With the Most Promising Sales Potential
  • Make More Informed Business Decisions from Insightful and In-Depth Analysis of Drug Performance
  • Obtain Sales Forecast for Drugs from 2012-2022 in China

Purchase a copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=114312.

Browse more reports on Respiratory Therapeutics Market http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/respiratory-therapeutics.

Contact sales (at) rnrmarketresearch (dot) com for further information.

About Us:

RnRMarketResearch.com is an online database of market research reports offers in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Read the full story at http://www.prweb.com/releases/china-non-small-cell-lung/drug-market-report/prweb11145242.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. China Human Rabies Vaccine Industry 2013 Analysis & 2017 Forecasts in New Research Report at RnRMarketResearch.com
2. 2013 China Medical Insurance Inflation Rates Revealed
3. China Poultry Vaccine Market Analysis
4. China Orthopedic Instrument Market 2013 Analysis & 2015 Forecasts in New Research Report at RnRMarketResearch.com
5. Medical Device Manufacturing in China Industry Research Report – Now Available from IBISWorld
6. China Independent Clinical Laboratory Industry Report, 2013-2015: Worldwide Industry Latest Market Share, Strategy, Growth, Size, Trends and Forecast Research Report 2015
7. Autonomous Clinical Laboratory Market in China 2013 Analysis & 2015 Forecasts in New Report Now Available at RnRMarketResearch.com
8. China BCAAs Market (Branched-Chain Amino Acids) Suppy & Forecasts in a New Research at ReportsnReports.com
9. Artisan Business Group Announces EB-5 China Trade Mission Itinerary
10. China Water and Air Pollution Impacts Food Supply Reports Water Advocate Sharon Kleyne
11. New risk model highlights arsenic risk in Chinas groundwater
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2016)... (PRWEB) , ... April 30, 2016 , ... “Aging well is a challenge for all of us, but there are ... Dr. Parul T. Kohli . “Research is showing more and more that there are simple, ... disease and disability as we age.” Top priorities Dr. Kohli’s recommends for her patients include;, ...
(Date:4/29/2016)... Dobbs Ferry, New York (PRWEB) , ... April 30, 2016 , ... ... and the Dobbs Ferry campus. The following programs will be expanding due to ... Resources Management (HRM). The expansion will begin this summer. , School ...
(Date:4/29/2016)... Hollywood, Fl (PRWEB) , ... April 29, 2016 ... ... was recently notified by the Accreditation Council for Graduate Medical Education (ACGME) that ... , This is the first accreditation of three residency programs that Memorial ...
(Date:4/29/2016)... Atlanta, Georgia (PRWEB) , ... April 29, 2016 , ... ... 60 rural hospitals across the Southeast, celebrated the signature of Gov. Nathan Deal on ... by Rep. Geoff Duncan (R - Cumming), offers a 70% tax credit to individuals ...
(Date:4/29/2016)... ... 2016 , ... The White House announced efforts yesterday to ... about their loan terms and accounts, and more protections for borrowers. The announcement ... private loans, has reached $1.3 trillion, with 43 million Americans holding student loans ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016 Dr. ... and Ste phen ... ArisGlobal®, a leading provider of cloud-based software solutions for life ... Pharmacovigilance team to bring a wealth of insight to a growing ... pharmacovigilance knowledge. George Phillips joined ArisGlobal in ...
(Date:4/28/2016)... , April 28, 2016  ValGenesis, Inc., ... Management Solutions (VLMS) today announced that a ... for sufferers of chronic kidney failure has ... manage their corporate validation process. The global ... software solution to manage their validation processes ...
(Date:4/27/2016)... 2016  Hologic, Inc. (Nasdaq: HOLX ... the fiscal second quarter ended March 26, 2016.  ... increased 41.2%, and non-GAAP diluted EPS of $0.47 ... on a reported basis, and 6.3% on a ... another good quarter, highlighted by 14.6% growth in ...
Breaking Medicine Technology: